Department of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, Tsu, Mie 514-8507, Japan.
Biol Pharm Bull. 2013;36(5):715-8. doi: 10.1248/bpb.b12-01102.
In recent years, drug delivery systems (DDS) have been developed, along with anticancer agents for those systems based on the concept of achieving a better clinical response and tolerability. Several clinical trials have shown that these drugs have better clinical effects in the treatment of many cancers, leading to their expanded indications. Liposomal doxorubicin is one DDS agent used to treat AIDS-related Kaposi's sarcoma and ovarian cancer in Japan. In addition to those two indications, the Food and Drug Administration (FDA) approved this drug for the treatment of multiple myeloma in 2007. Another DDS agent approved in Japan is nanoparticle albumin-bound paclitaxel, which has been used in the treatment of breast cancer. Most recently, this drug has been approved for the treatment of non-small cell lung cancer in the U.S.A. Although these DDS agents appear to be less toxic than conventional drugs, DDS-specific side effects such as various skin reactions, hypersensitivity reaction, and peripheral neuropathy sometimes occur. Therefore, medical staff must understand DDS anticancer agents fully, including characteristic side effects, to achieve the desired clinical outcomes.
近年来，已经开发出了药物传递系统（DDS），并基于实现更好的临床反应和耐受性的概念，为这些系统开发了抗癌药物。多项临床试验表明，这些药物在治疗许多癌症方面具有更好的临床效果，从而扩大了其适应证。多柔比星脂质体是一种用于治疗日本艾滋病相关卡波西肉瘤和卵巢癌的 DDS 药物。除了这两种适应证外，美国食品和药物管理局（FDA）于 2007 年批准该药用于治疗多发性骨髓瘤。另一种在日本获得批准的 DDS 药物是纳米白蛋白结合紫杉醇，已用于治疗乳腺癌。最近，该药已在美国获准用于治疗非小细胞肺癌。尽管这些 DDS 药物似乎比传统药物毒性更小，但有时会出现 DDS 特异性副作用，如各种皮肤反应、过敏反应和周围神经病。因此，医务人员必须充分了解 DDS 抗癌药物，包括其特征性副作用，以实现预期的临床效果。
